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donor chimerism and 0% HPDSC was observed. Median time
to neutrophil engraftment was 22 days post UCBT (range 13-
53 days). Only one of 9 patients developed grade II AGVHD.
Seven of 9 patients are alive at 80-460 days post UCBT. One
patient died from PTLD and one from GVHD and fungal
infection.
Summary: These preliminary results suggest that single or
double UCBT combined with unrelated HPDSC infusion in
children with malignant and non-malignant diseases is safe
and well tolerated. A larger cohort and longer follow-up will
be required to determine the safety and clinical signiﬁcance
of these early ﬁndings. (NCT01586455)
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Introduction: Allogeneic stem cell transplantation (HSCT)
and immunosuppressive therapy (IST) with anti-thymocyte
globulin (ATG) are standard treatment options for a child
with aplastic anemia (AA). Response to ATG however is much
lower in developing countries.
Patients and Methods: Retrospective analysis of pediatric
patients with AA (age < 15 years) who underwent sibling
donor HSCT or received IST at Christian Medical College,
Vellore India between 1990 andMarch 2014. Fanconi anemia
was excluded with stress cytogenetics. IST consisted of either
ALG (Pasteur Merieux) for 5 days or ATGAM (Pharmacia
Upjohn) for 4 days followed by steroids and cyclosporine for
12 months. Response was assessed at 6 months after IST.
Patients undergoing HSCT used either Cy/ATG or a Fludar-
abine based regimen for conditioning.
Results: 196 children [119 males and 77 females; median
age 10.2 years (range: 2-15)] were analysed of which 119
received IST and 77 underwent HSCT. Response to IST at 6
months was 36.1% with CR in 14.3% and PR in 21.8%.
Response rates were 7.7% in children with age < 5 years,
46.6% between ages 6-10 and 43.1% between 11-15 years.
Of the 43 responders, 13(30.2%) had relapse or clonal
evolution [9 had AA, 3 had AML and 1 had MDS]. Six pa-
tients had a repeat course of ATG while another 6 under-
went BMT. The 3 year OS for the entire group is 50 + 4.7%.
Of the 77 who underwent HSCT, 12 had conditioning with
Cy/ATG, 6 had Flu/Bu/ATG and 59 had Flu/Cy + ATG or TBI
200Cg. Graft source was bone marrow in 20 and PBSC in
57. Engraftment was seen in 62 (80.5%) while 15 had either
primary graft failure or expired due to sepsis within ﬁrst 2
weeks of HSCT. Acute GVHD was seen in 32.2% of patients
and chronic GVHD in 59.6% - mostly limited. The 3 year OS
for the entire group was 71.1 + 5.2% while for a cohort of 59
patients who had Flu/Cy conditioning, the 3 yr OS was 77.6
+ 5.5%.
A Superior 3 yr OS was seen with the use of Flu/Cy con-
ditioning for HSCT compared to ATG in all age groups. It was
83.3 + 10.8 vs 15.4 + 1.2 for age< 5 yrs and 74.1 +5.7 vs 52.6 +
3.7 for age > 5 years for HSCT and ATG respectively.
Conclusion: Sibling donor allogeneic HSCT is superior to IST
across all age groups in a large cohort of Indian childrenwith
aplastic anemia. Alternative donor transplants need to beexplored in patients who do not have a HLA identical sibling
donor.297
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Pretransplant pulmonary function test (PFT) abnormalities
are correlated with risk of early respiratory failure and
mortality in adults and older children. While there is an
increasing use of allogeneic BMT in infants and young chil-
dren with metabolic and immune deﬁciency disorders, lung
function has not been systematically studied in this age
group.We describe use of forced deﬂation PFT (dPFT), a novel
technique for assessment of lung function in a series of in-
fants and young children and those unable to perform
cooperative testing.
Forced dPFT studies were coordinated with other procedures
requiring general anesthesia and performed according to
previously published techniques1. Brieﬂy, a specially con-
structed forced deﬂation device was inserted between the
endotracheal tube and anesthesia breathing circuit via a 3-
way slide valve (Figure). The lungs were inﬂated three times
to 40 cm H2O (total lung capacity) and then rapidly deﬂated
to -40 cmH2O via a pneumotachograph (to residual volume).
Raw ﬂow or volume measurements were normalized and
converted to %predicted and standard deviation scores using
data obtained in healthy children.
Between October 2008 and April 2014, 52 dPFT studies were
performed in 26 transplant recipients. Indications for BMT
were inherited metabolic disease (42%), malignancy (31%),
primary immune deﬁciency (15%) and bone marrow failure
(12%). Median age of 21 patients who had pretransplant
studies was 0.91.3 y (0.1 e 4.9 y); nine of them (43%) had
one or more prior lung diseases (respiratory failure [n¼7];
pneumonia [n¼7]; ARDS [n¼3]; bronchopulmonary
dysplasia [n¼1]; and bronchitis [n¼1]). Forced vital capacity
(FVC) and forced expiratory ﬂow (FEF75) were normal in all
but respiratory system compliance (Crs) was reduced in 5/21
cases. Six out of nine (66.7%) patients with clinical resp. is-
sues pre-BMT also had respiratory complications post-BMT
compared with 3/12 (25%) that had no pre-transplant res-
piratory issues. There were no signiﬁcant differences in pre-
transplant FVC, FEF75 and Crs between those patients who
did and who did not have post-transplant pulmonary com-
plications with median follow-up of 1.71.5 y (p¼0.435,
p¼0.305, and p¼0.301 respectively). There were no compli-
cations during the procedures and dPFT studies could be
safely done in coordination with other procedures requiring
anesthesia.
In this pilot study, pre-transplant PFTs were not predictive of
post-transplant pulmonary complications, and most patients
had normal volume and ﬂows. A larger study would be
required to determine prevalence and signiﬁcance of lung
function abnormalities in infants and toddlers undergoing
transplantation.
Figure. (A) Forced deﬂation cart in operating room. (B) three way slide valve connected to ETT at nght. vacuum source and anesthesia circuit at left. (C) three
pneumotachs with medium sized one connected to slide valve (valve not shown)
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reactivity in premature infants with bronchopulmonary
dysplasia.” Am Rev Respir Dis 136(1): 50-57.298
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We present a case report of a child with sickle cell disease
who underwent a matched sibling bone marrow transplant
for cerebral vascular disease and associated moyamoya. At 4
years of age the patient had his ﬁrst abnormal transcranial
doppler ultrasound with elevated peak systolic velocity
(PSV) along the right and left middle cerebral artery (MCA).
Follow-up MRI revealed severe narrowing of the right-sided
M1 and A1 segments of the MCA along with evidence of
multiple prior ischemic events. MRI at 5 years of age showed
progressive and severe narrowing of the right MCA and the
anterior segment of the right anterior cerebral artery (ACA)
along with development of moyamoya. Follow up MRI
demonstrated near complete occlusion of the right MCA,
narrowing of the right ACA, and decreased perfusion within
the right anterior MCA territory. Because of his severe
and progressive cerebral vasculopathy requiring chronic
transfusion therapy, the patient underwent bone marrow
transplant as curative treatment for his sickle cell disease
with the intent to halt progression of his sickle cell inducedvasculopathy. The patient underwent a 10/10 matched sib-
ling donor transplant with Busulfan/Cyclophosphamide
conditioning and methotrexate/cyclosporine GVHD prophy-
laxis. Engraftment occurred with 100% donor chimerism.
Four months post-bone marrow transplant (BMT), MRI
showed stabilization of the progressive narrowing of the
right MCA and ACA. One year post-BMT there was improved
perfusion in the MCA distribution. On routine follow up 3
years post-transplant, MRI showed new and severe nar-
rowing of the left A1 segment along with evidence of interval
ischemia. Since BMT, the patient has beenwell appearing and
without any signs or symptoms of overt neurologic events.
His hemoglobin levels have been in the normal range (12.2-
13.5 g/dL) and his Hemoglobin S percentage has been 37%
(donor with sickle cell trait). He is currently undergoing a
preoperative evaluation for synangiosis surgery. Just as
chronic transfusion therapy with resulting reduction in the
Hemoglobin S percentage has been shown to halt progres-
sion of cerebral disease and prevent recurrent stroke in pa-
tients with sickle cell disease, it was hoped that curative
bone marrow transplant would do the same. Though this
